These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 31841547)
1. Ultra-deep massively parallel sequencing with unique molecular identifier tagging achieves comparable performance to droplet digital PCR for detection and quantification of circulating tumor DNA from lung cancer patients. Tran LS; Pham HT; Tran VU; Tran TT; Dang AH; Le DT; Nguyen SL; Nguyen NV; Nguyen TV; Vo BT; Dao HT; Nguyen NH; Tran TH; Nguyen CV; Pham PC; Dang-Mai AT; Dinh-Nguyen TK; Phan VH; Do TT; Truong Dinh K; Do HN; Phan MD; Giang H; Nguyen HN PLoS One; 2019; 14(12):e0226193. PubMed ID: 31841547 [TBL] [Abstract][Full Text] [Related]
2. Construction of a reference material panel for detecting Xu J; Qu S; Sun N; Zhang W; Zhang J; Song Q; Lin M; Gao W; Zheng Q; Han M; Na C; Xu R; Chang X; Yang X; Huang J J Clin Pathol; 2021 May; 74(5):314-320. PubMed ID: 32817175 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of a Liquid Biopsy Protocol using Ultra-Deep Massive Parallel Sequencing for Detecting and Quantifying Circulation Tumor DNA in Colorectal Cancer Patients. Nguyen HT; Tran DH; Ngo QD; Pham HT; Tran TT; Tran VU; Pham TN; Le TK; Le NT; Nguyen NM; Vo BT; Nguyen LT; Nguyen TV; Bui QTN; Nguyen HN; Luong BA; Le LGH; Do DM; Do TT; Hoang AV; Dinh KT; Phan MD; Tran LS; Giang H; Nguyen HN Cancer Invest; 2020 Feb; 38(2):85-93. PubMed ID: 31939681 [TBL] [Abstract][Full Text] [Related]
4. Diagnostic Strategies toward Clinical Implementation of Liquid Biopsy RAS/BRAF Circulating Tumor DNA Analyses in Patients with Metastatic Colorectal Cancer. van 't Erve I; Greuter MJE; Bolhuis K; Vessies DCL; Leal A; Vink GR; van den Broek D; Velculescu VE; Punt CJA; Meijer GA; Coupé VMH; Fijneman RJA J Mol Diagn; 2020 Dec; 22(12):1430-1437. PubMed ID: 32961317 [TBL] [Abstract][Full Text] [Related]
5. Non-invasive detection of actionable mutations in advanced non-small-cell lung cancer using targeted sequencing of circulating tumor DNA. Sim WC; Loh CH; Toh GL; Lim CW; Chopra A; Chang AYC; Goh LL Lung Cancer; 2018 Oct; 124():154-159. PubMed ID: 30268455 [TBL] [Abstract][Full Text] [Related]
6. Analytical and clinical validation of a novel amplicon-based NGS assay for the evaluation of circulating tumor DNA in metastatic colorectal cancer patients. Wang B; Wu S; Huang F; Shen M; Jiang H; Yu Y; Yu Q; Yang Y; Zhao Y; Zhou Y; Pan B; Liu T; Guo W Clin Chem Lab Med; 2019 Sep; 57(10):1501-1510. PubMed ID: 31339850 [TBL] [Abstract][Full Text] [Related]
7. Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer. Roosan MR; Mambetsariev I; Pharaon R; Fricke J; Husain H; Reckamp KL; Koczywas M; Massarelli E; Bild AH; Salgia R Chest; 2021 Sep; 160(3):1095-1107. PubMed ID: 33878340 [TBL] [Abstract][Full Text] [Related]
8. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer. Zhang Y; Xiong L; Xie F; Zheng X; Li Y; Zhu L; Sun J Cancer Med; 2021 Jul; 10(14):4697-4709. PubMed ID: 34173341 [TBL] [Abstract][Full Text] [Related]
9. Revolutionizing Non-Small Cell Lung Cancer Diagnosis: Ultra-High-Sensitive ctDNA Analysis for Detecting Hotspot Mutations with Long-term Stored Plasma. Lee JY; Jeon S; Jun HR; Sung CO; Jang SJ; Choi CM; Chun SM Cancer Res Treat; 2024 Apr; 56(2):484-501. PubMed ID: 37871897 [TBL] [Abstract][Full Text] [Related]
10. Actionable Mutation Profiles of Non-Small Cell Lung Cancer patients from Vietnamese population. Dang AH; Tran VU; Tran TT; Thi Pham HA; Le DT; Nguyen L; Nguyen NV; Thi Nguyen TH; Nguyen CV; Le HT; Thi Nguyen ML; Le VT; Nguyen PH; Vo BT; Thi Dao HT; Nguyen LT; Van Nguyen TC; Bui QN; Nguyen LH; Nguyen NH; Thi Nguyen QT; Le TX; Do TT; Dinh KT; Do HN; Phan MD; Nguyen HN; Tran LS; Giang H Sci Rep; 2020 Feb; 10(1):2707. PubMed ID: 32066856 [TBL] [Abstract][Full Text] [Related]
11. Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium. Li BT; Janku F; Jung B; Hou C; Madwani K; Alden R; Razavi P; Reis-Filho JS; Shen R; Isbell JM; Blocker AW; Eattock N; Gnerre S; Satya RV; Xu H; Zhao C; Hall MP; Hu Y; Sehnert AJ; Brown D; Ladanyi M; Rudin CM; Hunkapiller N; Feeney N; Mills GB; Paweletz CP; Janne PA; Solit DB; Riely GJ; Aravanis A; Oxnard GR Ann Oncol; 2019 Apr; 30(4):597-603. PubMed ID: 30891595 [TBL] [Abstract][Full Text] [Related]
12. Next-generation sequencing for tumor mutation quantification using liquid biopsies. Provencio M; Pérez-Barrios C; Barquin M; Calvo V; Franco F; Sánchez E; Sánchez R; Marsden D; Cristóbal Sánchez J; Martin Acosta P; Laza-Briviesca R; Cruz-Bermúdez A; Romero A Clin Chem Lab Med; 2020 Jan; 58(2):306-313. PubMed ID: 31469650 [TBL] [Abstract][Full Text] [Related]
13. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer. Villaflor V; Won B; Nagy R; Banks K; Lanman RB; Talasaz A; Salgia R Oncotarget; 2016 Oct; 7(41):66880-66891. PubMed ID: 27602770 [TBL] [Abstract][Full Text] [Related]
14. Development and clinical validation of a circulating tumor DNA test for the identification of clinically actionable mutations in nonsmall cell lung cancer. Liu L; Liu H; Shao D; Liu Z; Wang J; Deng Q; Tang H; Yang H; Zhang Y; Qiu Y; Cui F; Tan M; Zhang P; Li Z; Liu J; Liang W; Wang Y; Peng Z; Wang J; Yang H; Mao M; Kristiansen K; Ye M; He J Genes Chromosomes Cancer; 2018 Apr; 57(4):211-220. PubMed ID: 29277949 [TBL] [Abstract][Full Text] [Related]
15. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing. Guo Q; Wang J; Xiao J; Wang L; Hu X; Yu W; Song G; Lou J; Chen J Mol Cancer; 2018 Aug; 17(1):131. PubMed ID: 30153823 [TBL] [Abstract][Full Text] [Related]
16. Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer. Sacher AG; Paweletz C; Dahlberg SE; Alden RS; O'Connell A; Feeney N; Mach SL; Jänne PA; Oxnard GR JAMA Oncol; 2016 Aug; 2(8):1014-22. PubMed ID: 27055085 [TBL] [Abstract][Full Text] [Related]
17. Clinical utility of ctDNA by amplicon based next generation sequencing in first line non small cell lung cancer patients. Gristina V; Russo TDB; Barraco N; Gottardo A; Pepe F; Russo G; Fulfaro F; Incorvaia L; Badalamenti G; Troncone G; Malapelle U; Russo A; Bazan V; Galvano A Sci Rep; 2024 Sep; 14(1):22141. PubMed ID: 39333636 [TBL] [Abstract][Full Text] [Related]
18. Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non-Small Cell Lung Cancer. Schrock AB; Welsh A; Chung JH; Pavlick D; Bernicker EH; Creelan BC; Forcier B; Ross JS; Stephens PJ; Ali SM; Dagogo-Jack I; Shaw AT; Li T; Ou SI; Miller VA J Thorac Oncol; 2019 Feb; 14(2):255-264. PubMed ID: 30368012 [TBL] [Abstract][Full Text] [Related]
19. Circulating Tumor DNA Detection in Early-Stage Non-Small Cell Lung Cancer Patients by Targeted Sequencing. Chen KZ; Lou F; Yang F; Zhang JB; Ye H; Chen W; Guan T; Zhao MY; Su XX; Shi R; Jones L; Huang XF; Chen SY; Wang J Sci Rep; 2016 Aug; 6():31985. PubMed ID: 27555497 [TBL] [Abstract][Full Text] [Related]
20. Real-World Data of the Correlation between EGFR Determination by Liquid Biopsy in Non-squamous Non-small Cell Lung Cancer (NSCLC) and the EGFR Profile in Tumor Biopsy. Soria-Comes T; Palomar-Abril V; Ureste MM; Guerola MT; Maiques ICM Pathol Oncol Res; 2020 Apr; 26(2):845-851. PubMed ID: 30847713 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]